CHUNLI MEDICAL(SH:688236) Zheng Quan Zhi Xing·2025-03-28 14:51Core Viewpoint - The company has announced its expected daily related transactions for 2025, amounting to RMB 3.5 million, which are deemed necessary for normal business operations and do not harm the interests of the company or its shareholders, particularly minority shareholders [1][2][6]. Summary by Sections Daily Related Transactions Overview - The company held board and supervisory meetings on March 28, 2025, to approve the expected daily related transactions for 2025, with a total estimated expenditure of RMB 3.5 million [1][2]. - The transactions are considered normal business activities, adhering to principles of voluntariness, equivalence, and compensation, with fair pricing based on market rates [1][5]. Independent Director and Supervisory Board Opinions - The independent directors expressed agreement with the proposal, stating that the transactions align with the company's operational needs and do not harm the interests of all shareholders, especially minority shareholders [2][6]. - The supervisory board also reached a consensus that the expected daily related transactions are necessary for the company's operations and comply with relevant principles [2][6]. Expected Amount and Categories of Related Transactions - The company anticipates engaging in daily related transactions with Beijing Meizhuo Medical Equipment Co., Ltd. in 2025, with specific details to be outlined in subsequent agreements [2][3]. - The expected amount for 2025 is RMB 3.5 million, which is based on the previous year's actual transaction amounts [3][4]. Related Party Information - Beijing Meizhuo Medical Equipment Co., Ltd. is identified as a related party, with key personnel being relatives of the company's actual controller, but it does not exert majority control over the company [1][4]. - The company has confirmed that the related party has a good capacity to fulfill obligations, ensuring legal protection for the transactions [5][6]. Purpose and Impact of Related Transactions - The related transactions are necessary for the company's daily operations and are expected to benefit the company and all shareholders [5][6]. - The pricing of these transactions is deemed fair and reasonable, following the company's established procedures and market conditions [5][6]. Continuous Nature of Related Transactions - The company acknowledges that related party sales driven by customer demand are unavoidable, but it aims to keep the proportion of such transactions low [6]. Sponsor Institution's Review - The sponsor institution has verified that the expected daily related transactions have been approved by the board and supervisory board, with no objections raised regarding their necessity and fairness [6].